Nationwide Fund Advisors Increases Stake in Haemonetics Corp. (HAE)
Nationwide Fund Advisors boosted its position in Haemonetics Corp. (NYSE:HAE) by 1.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 40,719 shares of the company’s stock after buying an additional 623 shares during the period. Nationwide Fund Advisors owned 0.08% of Haemonetics Corp. worth $1,474,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. Tower Research Capital LLC TRC purchased a new position in Haemonetics Corp. during the second quarter worth approximately $133,000. PineBridge Investments L.P. increased its position in Haemonetics Corp. by 4.2% in the second quarter. PineBridge Investments L.P. now owns 6,473 shares of the company’s stock worth $187,000 after buying an additional 261 shares during the period. Teacher Retirement System of Texas increased its position in Haemonetics Corp. by 13.9% in the second quarter. Teacher Retirement System of Texas now owns 7,081 shares of the company’s stock worth $205,000 after buying an additional 865 shares during the period. Kirr Marbach & Co. LLC IN purchased a new position in Haemonetics Corp. during the second quarter worth approximately $210,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in Haemonetics Corp. during the second quarter worth approximately $217,000. Institutional investors and hedge funds own 99.51% of the company’s stock.
Haemonetics Corp. (NYSE:HAE) traded down 0.75% during midday trading on Monday, hitting $39.59. The stock had a trading volume of 268,088 shares. The company’s market cap is $2.05 billion. The stock’s 50 day moving average price is $36.25 and its 200-day moving average price is $33.49. Haemonetics Corp. has a 52 week low of $25.98 and a 52 week high of $39.96.
Haemonetics Corp. (NYSE:HAE) last announced its quarterly earnings data on Monday, November 7th. The company reported $0.46 EPS for the quarter, beating the Zacks’ consensus estimate of $0.35 by $0.11. The business earned $220.30 million during the quarter, compared to analyst estimates of $210.72 million. Haemonetics Corp. had a negative net margin of 6.48% and a positive return on equity of 10.99%. The firm’s revenue for the quarter was up .3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.44 earnings per share. Equities research analysts predict that Haemonetics Corp. will post $1.50 earnings per share for the current year.
WARNING: This article was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The original version of this article can be read at https://www.thecerbatgem.com/2016/11/29/nationwide-fund-advisors-increases-stake-in-haemonetics-corp-hae.html.
HAE has been the subject of a number of research reports. Zacks Investment Research downgraded Haemonetics Corp. from a “hold” rating to a “sell” rating in a research note on Wednesday, August 3rd. Off Wall Street initiated coverage on Haemonetics Corp. in a research note on Friday, October 14th. They issued a “sell” rating and a $24.00 target price for the company. Barrington Research upgraded Haemonetics Corp. from a “market perform” rating to an “outperform” rating and set a $41.00 target price for the company in a research note on Tuesday, November 8th. Sidoti downgraded Haemonetics Corp. from a “buy” rating to a “neutral” rating and set a $39.00 target price for the company. in a research note on Monday, August 15th. Finally, Benchmark Co. lifted their target price on Haemonetics Corp. from $28.00 to $32.00 and gave the company a “hold” rating in a research note on Tuesday, August 2nd. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the company’s stock. Haemonetics Corp. presently has a consensus rating of “Hold” and an average price target of $34.57.
Haemonetics Corp. Company Profile
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
Receive News & Stock Ratings for Haemonetics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corp. and related stocks with our FREE daily email newsletter.